MSU
REGN icon

Maple Securities USA’s Regeneron Pharmaceuticals REGN Stock Holding History

Maple Securities USA’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,444
Closed -$652K – 295
2015
Q1 		$652K Buy
+1,444
New +$612K 0.05% 83

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Maple Securities USA's REGN Position: Q2 2015 in Review

Maple Securities USA sold out of Regeneron Pharmaceuticals (REGN) in Q2 2015, closing a stake of 1,444 shares — an estimated $652K sold.

Maple Securities USA first reported a position in REGN in Q1 2015 and held it in 1 quarter. The position peaked at $652K in Q1 2015. 540 funds tracked by Wall St. Rank hold REGN as of Q2 2015.

  • Maple Securities USA reported no remaining Regeneron Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Maple Securities USA sold 1,444 Regeneron Pharmaceuticals shares in Q2 2015, an estimated $652K.
  • Maple Securities USA first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Maple Securities USA's Regeneron Pharmaceuticals position peaked at $652K in Q1 2015.
  • 540 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.